Pharmaceutical Technology on MSN
Mabwell and Aditum launch Kalexo Bio for siRNA therapy development
China’s Mabwell Bioscience and US-based Aditum Bio have launched Kalexo Bio, a new company, to develop a new small ...
China’s Mabwell (688062.SH) and Californian biotech venture firm Aditum Bio have combined to launch Kalexo Bio.
REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced ...
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that the National Medical Products Administration of China (NMPA ...
SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Sirius Therapeutics today announced that preliminary data from its Phase 1 clinical trial of SRSD107, a next generation siRNA therapeutic under clinical ...
Zacks Investment Research on MSN
NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy
Novartis (NVS) has entered into a licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (ARWR) for the latter’s ARO-SNCA. ARO-SNCA is Arrowhead’s preclinical stage siRNA therapy ...
SUWON, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the first patient has been successfully dosed in a ...
Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, announced today the successful submission of RN3161 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback